Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sensus HealthcareSRTS -0.42%59 3-Year Share Buyback Ratio is -0.20 as of Jun. 2026. GuruFocus rates SRTS with a GF Score™ of 59/100 and a GF Value™ of $2.42 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 612 Medical Devices & Instruments companies, Sensus Healthcare ranks better than 74.51% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sensus Healthcare's current 3-Year Share Buyback Ratio was -0.20%.
The historical rank and industry rank for Sensus Healthcare's 3-Year Share Buyback Ratio or its related term are showing as below:
SRTS'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -6.9 Med: -0.1 Max: 0.2
Current: -0.2
During the past 13 years, Sensus Healthcare's highest 3-Year Share Buyback Ratio was 0.20%. The lowest was -6.90%. And the median was -0.10%.
SRTS's 3-Year Share Buyback Ratio is ranked better than 74.51% of 612
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs SRTS: -0.20
Sensus Healthcare (NAS:SRTS) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Sensus Healthcare 3-Year Share Buyback Ratio Related Terms
SRTS vs POSC, XTNT, MYO: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Sensus Healthcare's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensus Healthcare 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sensus Healthcare's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Sensus Healthcare's 3-Year Share Buyback Ratio falls into.
Sensus Healthcare 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -0.20 mean?
Sensus Healthcare (SRTS) has a 3-Year Share Buyback Ratio of -0.20 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sensus Healthcare and its competitors. According to the industry distribution chart, Sensus Healthcare ranks #156 out of 612 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Sensus Healthcare's 3-Year Share Buyback Ratio too high?
Sensus Healthcare's current 3-Year Share Buyback Ratio is -0.20. Based on the distribution chart, Sensus Healthcare ranks #156 out of 612 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sensus Healthcare has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's 3-Year Share Buyback Ratio compare to POSC and XTNT?
According to the Medical Devices & Instruments industry distribution chart, Sensus Healthcare ranks #156 out of 612 companies for 3-Year Share Buyback Ratio. This puts Sensus Healthcare in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Sensus Healthcare and its competitors. Sensus Healthcare's current 3-Year Share Buyback Ratio is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.42, compared to a current price of $3.53 — trading 45.9% above its estimated fair value. The current 3-Year Share Buyback Ratio is -0.20. Sensus Healthcare's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current 3-Year Share Buyback Ratio is -0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sensus Healthcare (SRTS) Overvalued in 2026?
Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued.
The current stock price of $3.53 is trading 45.9% above its estimated GF Value™ of $2.42.
GuruFocus considers Sensus Healthcare to be Significantly Overvalued.
Key valuation signals for SRTS:
3-Year Share Buyback Ratio: -0.20
GF Value™: $2.42 vs. price of $3.53 (45.9% above fair value)
No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
59GF Score
Get the complete analysis for SRTS
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTS has been successfully added to your 
